Diclofenac Potassium是一种强效的非选择性环氧化酶（COX）抑制剂，在CHO细胞中对人源COX-1和COX-2的IC₅₀值分别为4nM和1.3nM；对羊源COX-1和COX-2的IC₅₀值分别为5.1μM和0.84μM。
Cas No.:15307-81-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Diclofenac Potassium is a potent, non-selective cyclooxygenase (COX) inhibitor, with IC₅₀ values of 4nM and 1.3nM for human COX-1 and COX-2, respectively, in CHO cells, and 5.1μM and 0.84μM for ovine COX-1 and COX-2, respectively[1][2]. Diclofenac Potassium is a nonsteroidal anti-inflammatory drug (NSAID) widely used in clinical practice for its anti-inflammatory, analgesic, and antipyretic effects[3].
In vitro, Diclofenac Potassium (10-200mM; 24-72h) inhibited the proliferation of HepG2 and Hep3B cells in a dose-dependent manner. After 48h of treatment at 50mM, the inhibition rates are 40.47% and 54.49% for HepG2 and Hep3B cells, respectively, with IC₅₀ values of 70.54mM and 48.39mM[4]. Diclofenac Potassium (10-200mM; 24-72h) also upregulated COX-2 mRNA expression in both cell lines[4]. Diclofenac Potassium (0-60μM, 24-48h) dose-dependently inhibited neurite outgrowth and neuronal differentiation of neural stem cells (NSCs), and induced NSC death via activation of the caspase signaling cascade[3].
In vivo, Administration of Diclofenac Potassium (3mg/kg; twice daily for 5 days; p.o.) in male SD rats disrupted gastrointestinal integrity, resulting in a significant increase in fecal ⁵¹Cr excretion[1]. Oral Diclofenac Potassium (3mg/kg/d) for 15 days significantly reduced edema by day 3 and exhibited anti-hyperalgesic effects by day 9 in the rat model of repeated arthritis[5].
References:
[1] Riendeau D, Percival MD, Boyce S, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997;121(1):105-117.
[2] Labib MB, Sharkawi SMZ, El-Daly M. Design, synthesis of novel isoindoline hybrids as COX-2 inhibitors: Anti-inflammatory, analgesic activities and docking study. Bioorg Chem. 2018;80:70-80.
[3] Kudo C, Kori M, Matsuzaki K, et al. Diclofenac inhibits proliferation and differentiation of neural stem cells. Biochem Pharmacol. 2003;66(2):289-295.
[4] Chen NN, Wu SG. Nan Fang Yi Ke Da Xue Xue Bao. 2006;26(6):814-817.
[5] Peter-Szabo, Mihaly et al. “Quantitative characterization of a repeated acute joint inflammation model in rats.” Clinical and experimental pharmacology & physiology vol. 34,5-6 (2007): 520-6.
Diclofenac Potassium是一种强效的非选择性环氧化酶（COX）抑制剂，在CHO细胞中对人源COX-1和COX-2的IC₅₀值分别为4nM和1.3nM；对羊源COX-1和COX-2的IC₅₀值分别为5.1μM和0.84μM[1][2]。Diclofenac Potassium是一种非甾体抗炎药（NSAID），因其具有抗炎、镇痛和解热作用而被广泛应用于临床[3]。
体外实验中，Diclofenac Potassium（10-200mM；24-72h）以剂量依赖性方式抑制HepG2和Hep3B细胞的增殖。在50mM处理48h后，对HepG2和Hep3B细胞的抑制率分别为40.47%和54.49%，其IC₅₀值分别为70.54mM和48.39mM[4]。Diclofenac Potassium（10-200mM；24-72h）还上调了这两种细胞系中的COX-2 mRNA表达水平[4]。Diclofenac Potassium（0-60μM；24-48h）以剂量依赖的方式抑制神经干细胞（NSCs）的神经突起生长及向神经元的分化，并通过激活caspase信号级联反应诱导NSCs死亡[3]。
体内实验中，Diclofenac Potassium（3mg/kg；每日两次连续5天；口服）在雄性SD大鼠中可破坏胃肠道完整性，导致粪便中⁵¹Cr排泄显著增加[1]。口服Diclofenac Potassium（3mg/kg/天）连续15天在反复关节炎大鼠模型中于第3天显著减轻水肿，在第9天表现出抗痛觉作用[5]。
| Cell experiment [1]: | |
Cell lines | HepG2, Hep3B and QSG-7701 |
Preparation Method | After exposure to Diclofenac Potassium at various concentrations (10-200mM) for 24, 48 and 72h, the cell proliferation was analyzed by Cell Counting Kit-8 (CCK-8) assay and mRNA expression determined by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). |
Reaction Conditions | 10-200mM; 24, 48 and 72h |
Applications | Diclofenac Potassium exposure for 24, 48 and 72h significantly inhibited HepG2 and Hep3B cell proliferation in a concentration-dependent manner, with inhibition rate of 40.47% and 54.49% after 48h exposure to 50mM and IC50 of 70.54 and 48.39mM, respectively. A much weaker anti-proliferative effect on QSG-7701 cells was shown, with IC50 of 189.91mM after 48h exposure to Diclofenac Potassium. RT-PCR detected COX-2 mRNA in HepG2 and Hep3B cells, but hardly in QSG-7701 cells. Treatment with Diclofenac Potassium resulted in elevated COX-2 mRNA expression both in HepG2 and Hep3B cells. |
| Animal experiment [2]: | |
Animal models | Male Sprague-Dawley rats |
Preparation Method | Male Sprague-Dawley rats were dosed orally with Diclofenac Potassium 3mg/kg twice daily (b.i.d.) for 5 days. A plasma sample was obtained 1h after the morning dose on day 4 for measurement of drug concentration. Immediately after the administration of the last dose on day 5, the rats were injected via a tail vein with 0.5ml of 51Cr-labelled red blood cells from a donor rat after incubation with sodium 51chromate. The rats were placed individually in metabolism cages with food and water ad libitum. Faeces were collected for a 48h period and 51Cr faecal excretion was calculated as a % of total injected dose (20μCi per animal) |
Dosage form | 3mg/kg; b.i.d.; p.o. |
Applications | Administration of Diclofenac Potassium at 3mg/kg, b.i.d., for 5 days resulted in a significant increase in faecal 51Cr excretion. |
References: | |
| Cas No. | 15307-81-0 | SDF | |
| 别名 | 双氯芬酸钾 | ||
| 化学名 | potassium;2-[2-(2,6-dichloroanilino)phenyl]acetate | ||
| Canonical SMILES | C1=CC=C(C(=C1)CC(=O)[O-])NC2=C(C=CC=C2Cl)Cl.[K+] | ||
| 分子式 | C14H10Cl2KNO2 | 分子量 | 334.24 |
| 溶解度 | ≥ 14.95mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9919 mL | 14.9593 mL | 29.9186 mL |
| 5 mM | 598.4 μL | 2.9919 mL | 5.9837 mL |
| 10 mM | 299.2 μL | 1.4959 mL | 2.9919 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet